Information Amenamevir Amenamevir (ASP2151) is a potent helicase-primase inhibitor and a novel class of antiviral agent. Targets helicase-primase In vitro ASP2151 inhibited the in vitro replication of HSV-1. The mean EC50s of ASP2151 against HSV-1 and HSV-2 were 14 (range, 7.7 to 20) and 30 ng/ml (range, 15 to 58), respectively. In vivo In the cutaneously HSV-1-infected mouse model, ASP2151 dose dependently suppressed intradermal HSV-1 growth, with the effect reaching a plateau at a dose of 30 mg/kg of body weight/day.